Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kalvista Pharmaceuticals Inc (NQ: KALV )

7.080 +0.060 (+0.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 304,266
Open 7.160
Bid (Size) 5.000 (4)
Ask (Size) 8.600 (1)
Prev. Close 7.020
Today's Range 6.910 - 7.160
52wk Range 4.120 - 17.06
Shares Outstanding 34,169,438
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results
From KalVista Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga

Performance

YTD
+6.79%
+6.79%
1 Month
-9.35%
-9.35%
3 Month
+36.68%
+36.68%
6 Month
-52.80%
-52.80%
1 Year
-52.99%
-52.99%

More News

Read More
KalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
KalVista Pharmaceuticals Provides Progress Updates on Sebetralstat Development
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in The Lancet
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Presents Data at Western Society of Allergy, Asthma & Immunology (WSAAI) 60th Annual Scientific Session
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Gold Rises Over 1%; Elys Game Technology Shares Spike Higher
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Major Indexes Falter As Rocky Year Wraps Up
Via Talk Markets
Dow Rises 100 Points; Crude Oil Rises Over 1%
Via Benzinga
Why Shares of Chinese Companies Are Trading Higher? Here Are 55 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
KalVista Pharmaceuticals Announces $58 Million Registered Direct Offering
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.